Consensus recommendation on the development of cardiovascular disease polypill in China

Chinese Journal of Cardiology

Volumn 41, Issue 2, 2013, Pages 91-93

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; CHINA; HUMAN; POLYPHARMACY; PRACTICE GUIDELINE;

CARDIOVASCULAR DISEASES; CHINA; DRUG COMBINATIONS; DRUG DESIGN; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 84875789409     PISSN: 02533758     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0253-3758.2013.02.002     Document Type: Article

References (14)

1. 2011, 39:3-22.
2. Ndindjock R, Gedeon J, Meudis S, et al. Potential impact of single-risk-factor versus total risk management for the prevention of cardiovascular events in Seychelles. Bull World Health Organ, 2011, 89: 286-295.
3. Wald N J, Law M R. A strategy to reduce cardiovascular disease by more than 80%. BMJ, 2003, 326: 1419.
4. Carey K M, Comee M R, Donovan J L, et al. A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke. Ann Pharmacother, 2012, 46: 688-695.
5. Endres M, Heuschmann P U, Laufs U, et al. Primary prevention of stroke: blood pressure, lipids, and heart failure. Eur Heart J, 2011, 32:545-552.
6. Rubinstein A, García Marti S, Souto A, et al. Generalized cost-effectiveness analysis of a package of interventions to reduce cardiovascular disease in Buenos Aires, Argentina. Cost Eff Resour Alloc, 2009, 7: 10.
7. Zamorano J, Erdine S, Pavia A, et al. Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial. Curr Med Res Opin, 2011, 27:821-833.
8. Indian Polycap Study (TIPS), Yusuf S, Pais P, et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet, 2009, 373: 1341-1351.
9. Malekzadeh F, Marshall T, Pourshams A, et al. A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors. Int J Clin Pract, 2010, 64: 1220-1227.
10. Soliman E Z, Mendis S, Dissanayake W P, et al. A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization. Trials, 2011, 12:3.
11. PILL Collaborative Group, Rodgers A, Patel A, et al. An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk. PLoS One, 2011, 6: e19857.
12. Selak V, Elley C R, Crengle S, et al. IMProving Adherence using Combination Therapy (IMPACT): design and protocol of a randomised controlled trial in primary care. Contemp Clin Trials, 2011, 32:909-915.
13. Liu H, Patel A, Brown A, et al. Rationale and design of the Kanyini guidelines adherence with the polypill (Kanyini-GAP) study: a randomised controlled trial of a polypill-based strategy amongst indigenous and non indigenous people at high cardiovascular risk. BMC Public Health, 2010, 10:458.
14. Sanz G, Fuster V, Guzmán L, et al. The fixed-dose combination drug for secondary cardiovascular prevention project: improving equitable access and adherence to secondary cardiovascular prevention with a fixed-dose combination drug. Study design and objectives. Am Heart J, 2011, 162:811-817.